Long-term outcomes in African American kidney transplant recipients under contemporary immunosuppression: a four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study

2013 ◽  
Vol 28 (2) ◽  
pp. 184-191 ◽  
Author(s):  
Mohanram Narayanan ◽  
Oleh Pankewycz ◽  
Fuad Shihab ◽  
Anne Wiland ◽  
Kevin McCague ◽  
...  
Keyword(s):  
African American ◽  
Renal Transplant ◽  
Kidney Transplant ◽  
Mycophenolic Acid ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Long Term Outcomes

Long‐term outcomes of pediatric kidney transplant recipients with a pretransplant malignancy

2019 ◽  
Vol 23 (7) ◽  
Author(s):  
Oscar K. Serrano ◽  
Alexis Gannon ◽  
Ayokunle S. Olowofela ◽  
Apoorva Reddy ◽  
Danielle Berglund ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Long Term Outcomes

scholarly journals Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Brian P. Boerner ◽  
Clifford D. Miles ◽  
Vijay Shivaswamy
Keyword(s):  
Renal Transplantation ◽  
Renal Transplant ◽  
Kidney Transplant ◽  
Hemoglobin A1c ◽  
Renal Transplant Recipients ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
First Line ◽  
New Onset

New-onset diabetes after transplantation (NODAT) is a common comorbidity after renal transplantation. Though metformin is the first-line agent for the treatment of type 2 diabetes, in renal transplant recipients, metformin is frequently avoided due to concerns about renal dysfunction and risk for lactic acidosis. Therefore, alternative first-line agents for the treatment of NODAT in renal transplant recipients are needed. Sitagliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, has a low incidence of hypoglycemia, is weight neutral, and, in a small study, did not affect immunosuppressant levels. However, long-term sitagliptin use for the treatment of NODAT in kidney transplant recipients has not been studied. We retrospectively analyzed renal transplant recipients diagnosed with NODAT and treated with sitagliptin to assess safety and efficacy. Twenty-two patients were started on sitagliptin alone. After 12 months of followup, 19/22 patients remained on sitagliptin alone with a significant improvement in hemoglobin A1c. Renal function and immunosuppressant levels remained stable. Analysis of long-term followup (32.5±17.8 months) revealed that 17/22 patients remained on sitagliptin (mean hemoglobin A1c < 7%) with 9/17 patients remaining on sitagliptin alone. Transplant-specific adverse events were rare. Sitagliptin appears safe and efficacious for the treatment of NODAT in kidney transplant recipients.

scholarly journals Association of Slow Graft Function with Long-Term Outcomes in Kidney Transplant Recipients

2018 ◽  
Vol 23 ◽  
pp. 224-231 ◽  
Author(s):  
Connie J. Wang ◽  
Ahmad Tuffaha ◽  
Milind A. Phadnis ◽  
Jonathan D. Mahnken ◽  
James B. Wetmore
Keyword(s):  
Kidney Transplant ◽  
Graft Function ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Long Term Outcomes
Sign in / Sign up

Export Citation Format

Share Document